Purpose: This phase I study of paclitaxel and oral etoposide was performed to determine the safety of the combination in patients with advanced lung cancer who had received no prior chemotherapy, and to identify a dose for phase II testing.
Introduction
Carcinoma of the lung remains the most common cause of cancer death in most Western countries. In many countries, efforts aimed at smoking reduction and cessation have succeeded in reducing the lung cancer incidence in men, although, the incidence in women continues to rise. The available treatment modalities are unable to cure the majority of patients who present with lung cancer; these patients often receive palliative chemotherapy and radiotherapy. However, for nonsmall-cell lung cancer (NSCLC) the benefits of chemotherapy are relatively small [1] , while in small-cell lung cancer (SCLC) initial good responses are only rarely maintained in the long term. Thus more effective chemotherapeutic combinations are needed.
Paclitaxel is a relatively new anticancer agent which acts by producing stabilization of microtubules. It has activity in both small-cell and non-small-cell carcinoma of the lung [2, 3] , and promising results have been reported for this drug, both as a single agent [4] [5] [6] and in combination with other drugs [7, 8] .
Etoposide, an epipodophyllotoxin which inhibits the action of topoisomerase II, has activity against a broad range of tumours. It is frequently used in combination chemotherapy for both SCLC and NSCLC. Etoposide has been used in both intravenous and oral formulations.
Conflicting results have been reported from preclinical studies combining paclitaxel and etoposide. Whilst some studies have suggested a synergistic interaction between the two drugs [9, 10] , others have demonstrated antagonism [11, 12] . Furthermore, findings concerning the optimal sequencing of these agents in vitro have been inconsistent [9, 10] .
We have carried out a phase I trial of the combination of paclitaxel and etoposide, given by two different sequences, in patients with lung cancer. The aims of this study were to determine the safety of this combination and to define a dose of the drugs to be used in subsequent phase II evaluation.
Patients and methods
Patients were required to have histologically or cytologically proven, locally advanced, locally recurrent or metastatic NSCLC or extensive SCLC. Patients were not permitted to have received prior chemotherapy, although prior radiation therapy was allowed, provided it had been completed at least four weeks prior to study entry and included <25% of the bone marrow volume. Other eligibility requirements included: age of 18 to 75 years; ECOG performance status of 0-2; neutrophil count of »2 x 10 9 /l and platelet count of 5 100 x 10 9 /l; normal serum calcium; bilirubin < 1.5 times the upper limit of normal (ULN) for the institution and transaminases < 2.5 times ULN for the institution; and serum creatinine <1.5 times ULN for the institution or a measured glomerular filtration rate of > 60 ml/min. The protocol was approved by the ethics committee at each participating institution, and written informed consent was obtained from all patients. Patients with symptomatic cerebral metastases or in whom the central nervous system was the sole site of metastatic disease were excluded. They were also excluded if they had experienced a prior malignancy, had significant underlying cardiac, neurologic or psychiatric disease, or if they had active uncontrolled infection. Patients with co-existing gastrointestinal disease or vomiting/diarrhoea were not eligible for the study. Pregnant or lactating females were not permitted to enter the study.
At the time of study entry all patients were evaluated with a history and physical examination, a full blood count (FBC) and differential, serum electrolytes and liver function tests (LFT), and an electrocardiogram. Radiological investigations included a chest X-ray, and computerised tomographic scan of the chest and abdomen. A bone scan was performed in all patients with SCLC, and in patients with NSCLC who had symptoms or signs suggestive of bony involvement. Patients with SCLC underwent bone marrow aspiration and trephine biopsy.
While on study, patients were seen weekly and evaluated for symptoms of toxicity. Electrolytes and LFT were measured weekly, while a FBC was performed twice weekly. A chest X-ray was performed prior to each cycle of treatment. Every nine weeks (three cycles of treatment) all baseline investigations were repeated.
Treatment-related toxicity was graded according to the WHO criteria [13] . All patients were required to have measurable or evaluable disease, and ECOG response criteria were used [14] . Improvements in disease had to persist for at least four weeks before being considered a response. For responding patients, duration of response was measured from the commencement of protocol treatment until the development of progression or relapse. Overall survival was calculated from the commencement of protocol treatment to death. Response and survival times were calculated using the life table method.
Patients were treated with paclitaxel (Taxol, Bristol-Myers Squibb, Princeton NJ) and oral etoposide (Vepesid capsules, Bristol-Myers Squibb, Princeton NJ). Paclitaxel was administered as a three hour infusion. Patients received premedication with oral dexamethasone and intravenous diphenhydramine and cimetidine.
The starting dose of paclitaxel was 100 mg/m 2 , and this was increased by 20 mg/m 2 in each subsequent dose level. For each dose level, two different schedules of drug administration were used, with paclitaxel being given either on day 1 (schedule A) or day 5 (schedule B) of a 21 day cycle. Etoposide was given on days 1 to 5, as a fixed single oral dose of 100 mg (2 x 50 mg capsules) each morning. On days when both were to be given, etoposide was administered prior to the commencement of the paclitaxel infusion. A maximum of nine cycles of treatment could be administered to patients who did not display evidence of disease progression. Colony stimulating factors were not used.
A minimum of three patients were treated at each dose level on schedules A and B. If no dose limiting toxicity (DLT) was observed during the first cycle of treatment, accrual continued at the next dose level. If an episode of DLT occurred, up to six patients were treated at that level. If DLT occurred in >2 of these six patients, then accrual to that schedule was ceased. DLT was defined in advance as any one of: grade 4 neutropenia or leukopenia lasting > 7 days; febrile neutropenia (absolute neutrophil count < 5 x 1O 9 /1 and oral temperature > 38.5 °C); platelet count < 20 x 10 9 /l; grade 3 or 4 non hematological toxicity other than alopecia or nausea. The maximum tolerated dose was defined as one dose level below that for which dose limiting toxicity was documented, using whichever schedule resulted in a higher paclitaxel dose. A total of six patients were to be treated at this dose.
In individual patients who experienced dose limiting toxicity, the dose of paclitaxel was reduced to the next lowest level for subsequent cycles. There were no modifications to the etoposide dose. Treatment could also be delayed for up to three weeks in patients in whom neutrophil and platelet counts had not returned to normal by the planned day of treatment. Patients with DLT (cycle 1)
1 Cycles in which the dose of paclitaxel was reduced because of previous toxicity are displayed at the dose actually given, rather than at the starting dose. b One patient was inadvertently treated at a dose of 80 mg/m 2 of paclitaxel rather than the designated dose of 100 mg/m 2 .
Results
Between October 1994 and October 1995, 49 patients were entered on this study, and their characteristics are given in Table 1 . A total of 254 cycles were given to these patients, with a median of three cycles per patient (range 1-9). All patients are evaluable for toxicity. DLT occurred at different levels on the two schedules, and the distribution of these toxicities by schedule and level, for the first cycle of treatment, together with the numbers of patients treated at each level is shown in Table 2 . There were no treatment-related deaths. On schedule A, dose limiting toxicity occurred in three of six patients receiving a paclitaxel dose of 220 mg/m 2 . The first of these patients experienced grade 3 mucositis, and grade 3 myalgia, in the first cycle of treatment. The second patient developed grade 3 diarrhoea, requiring hospital admission and intravenous hydration. Although this toxicity resolved, the patient received no further protocol therapy. The final patient developed grade 3 sensory neurotoxicity following cycle 1. This resolved, but recurred following a second cycle of treatment, at reduced dose. The patient then received no further therapy.
On schedule B, febrile neutropenia occurred in two patients at a paclitaxel dose of 160 mg/m 2 . In one case, this was associated with pneumonia, whilst in the other, no source of sepsis was detected. Both patients recovered from these episodes, with one receiving no further therapy, and the other continuing to nine cycles at reduced dose. No dose escalation occurred on schedule B beyond this dose level.
The major toxicities of treatment were leukopenia and neutropenia, which were evaluable in 250 cycles (98% of all cycles administered). The occurrence of neutropenia is summarised in Table 3 . The mean time to the neutrophil nadir was 11.7 days. This did not differ significantly between dose levels or between the two schedules used. There were no episodes of grade 4 neutropenia that lasted seven days or longer, and there were only three episodes of febrile neutropenia. The severity of leukopenia and neutropenia was significantly associated with the dose level that patients received (P < 0.01, Pearsons R statistic). However, there was no cumulative effect with successive cycles of treatment.
Other hematologic toxicity was mild. Thrombocytopenia did not occur, and anemia was a rare problem with only five patients requiring transfusion of a total of 18 units of packed red blood cells.
Non-hematological toxicity was mild, with no episodes of grade 4 toxicity. The most common non-hematological toxicities (and the percentage of cycles in which they were grade 3) were diarrhoea (1.2%), myalgia/ arthralgia (2.8%), fatigue (0.8%), nausea or vomiting (0.8%), peripheral neuropathy (0.4%), and stomatitis (0.8%). Grade 3 neuropathy occurred in 1.4% of cycles with a paclitaxel dose of > 160 mg/m 2 . The severity of peripheral neuropathy was correlated with the dose of paclitaxel administered (P < 0.05, Pearsons R statistic). For the other toxicities, there was no such association. In addition to the toxicities described above, reversible total alopecia occurred in almost all patients having more than three cycles of treatment.
Hypersensitivity reactions occurred in two patients. One patient, a male aged 54 on level 5A, experienced a reaction characterised by agitation, hypertension and facial flushing during the first five minutes of his first cycle of treatment. This resolved over 30 minutes, following cessation of the paclitaxel infusion. A second patient, a 45-year-old female enrolled on level 4B, experienced a similar reaction within a few minutes of commencing her second paclitaxel infusion. Once again, this resolved with discontinuation of the paclitaxel. Although eligible for rechallenge, both patients elected not to receive further study treatment.
Although this was a phase I study, all patients had measurable or evaluable disease, and response to treatment was therefore examined. Amongst the 45 patients with NSCLC there were three complete and eight partial responses, for an overall response rate of 24% (95% confidence interval, 13%-40%). Of the seven patients with previously untreated locally advanced disease, there were three responses (42.9%; 9.9%-81.7%), while there were eight responses amongst the 37 patients with metastatic disease (21.6%; 9.8%-38.2%). Responses occurred at all dose levels and on both schedules of administration. For the responding patients, the median duration of response was 53 weeks. In the patients with SCLC, there was one complete response, while the other three patients had progressive disease. Overall, 24 of the patients have died, and 23 are alive with evidence of disease. Two patients, both of whom had metastatic NSCLC, remain alive and in complete remission 16 and 9 months after commencing treatment. For the patients with NSCLC, the median overall survival is 50 weeks.
Discussion
The treatment of lung cancer with cytotoxic drugs remains far from ideal. Although high response rates are achieved in SCLC, most patients ultimately relapse and die from their disease. In NSCLC, cytotoxic treatment has been associated with relatively low response rates, and the impact on survival has been small [1] . In addition, there is a perception that currently available treatments produce toxicity which cannot be justified by the benefits achieved. New treatments are therefore required for both SCLC and NSCLC.
This phase I study evaluated the safety and tolerability of paclitaxel and oral etoposide, when administered by two different schedules. The results indicate that the combination of paclitaxel 200 mg/m 2 intravenously over three hours on day 1, and oral etoposide 100 mg daily for five days can be given safely to patients with carcinoma of the lung. Diarrhoea and myalgia are dose-limiting toxicities above this level. On an alternate schedule, with paclitaxel given on day 5, dose limiting toxicity occurred at a paclitaxel dose of 160 mg/m 2 . The major toxicity of the combination was neutropenia. This was a frequent occurrence, and only at the lowest dose levels did grade 3 or 4 neutropenia occur in less than half of the cycles administered, despite this, febrile neutropenia was uncommon. Apart from myelosuppression, the combination was well tolerated, irrespective of the administration schedule used. Other than at the highest dose level tested (above the dose recommended for future phase II trials) did these non-hematological toxicity produce a major impact on patient management.
Growth factors were not used in this study. On schedule B, it is possible that the use of these agents may have permitted further dose escalation, since the dose limiting toxicity was febrile neutropenia. On schedule A, however, the dose limiting toxicity was not directly related to myelosuppression, so it is doubtful whether the use of growth factors would have resulted in a higher MTD.
Although this study was not designed to determine the response rate of lung tumours to the combination of paclitaxel and etoposide, responses were seen at all dose levels and on both schedules, particularly in patients with NSCLC. These results provide encouragement that this may be an active regimen. However, appropriately designed phase II studies will be required to determine the activity of this combination.
Paclitaxel has been combined with etoposide in two previous phase I studies in patients with advanced cancer [15, 16] . In the first of these [15] , 29 patients were treated with oral etoposide at a dose of 50 mg twice daily for 10 days, with paclitaxel given as a three hour infusion on day 10. The recommended dose of paclitaxel using this schedule was 150 mg/m 2 . The administration of higher doses of paclitaxel required the use of G-CSF. Two partial responses were observed in this study, both in patients with NSCLC, who had previously received cisplatin-containing chemotherapy. When compared to our study, the lower recommended phase II dose is probably the result of the higher dose of etoposide used.
In a second study a three-hour infusion of paclitaxel was combined with intravenous etoposide at a dose of 100 mg/m 2 daily for three days [16] . Paclitaxel was given on day 3, with a starting dose of 80 mg/m 2 and with the aim of determining the maximum tolerated dose both with and without G-CSF. Only preliminary results of this study have been reported, with accrual continuing at a paclitaxel dose of 100 mg/m 2 . In both of these studies, paclitaxel was given following etoposide, with the decision to use this sequence being based on preclinical information. We found that higher doses of paclitaxel could be administered when it was given before etoposide. However our study was not designed to compare the efficacy of the different schedules of administration.
Paclitaxel has also been combined with etoposide together with other drugs for the treatment of NSCLC or SCLC [17] [18] [19] . These included carboplatin and ifosfamide [19, 20] , carboplatin alone [17] , or cisplatin [18, 21] . In addition, radiotherapy was also used in one of these studies [21] .
In these phase I and II studies, doses of paclitaxel have ranged from 135 mg/m 2 to 225 mg/m 2 given by a one- [21] , three- [18] or 24-hour [19] infusion. The etoposide was given by several different schedules, including 50 mg/m 2 intravenously on day 1 followed by oral etoposide 100 mg/m 2 for two days [18] , 100 mg/m 2 intravenously for three days [21] , and oral etoposide given for 10 days, alternating between 100 mg and 50 mg [17] . Response rates in NSCLC ranged from 27% to 42% [19, 21] , while in SCLC responses occurred in 76% to 100% of patients [17, 18] . Because of the inclusion of other cytotoxic drugs in these studies as well as the different duration of paclitaxel infusion, it is difficult to compare directly the doses attained and responses observed with those from our study.
The combination of paclitaxel and oral etoposide can be administered safely, and with low toxicity to patients with lung cancer. In addition, both paclitaxel and etoposide have a broad spectrum of activity against other cancers, and this combination may be useful in other diseases. The recommended dose for phase II studies is paclitaxel 200 mg/m 2 given on day one, with etoposide 100 mg orally for five days. Phase II studies will be necessary to determine the efficacy of this treatment, but the occurrence of responses in this phase I study provides encouragement that this may be an active regimen.
